Drug,Generic,Indication,Dosage,Frequency,Rate Administered,How Supplied,Vial Sizes,Dilution Solution,Reconstitution Solution,Side Effects,NS Bags/D5W,Overfill,Pre-med Recommendation,Filters,Storage and Handling,Extended Stability,BBW,Special Notes,Additional Notes,Pregnancy Category
ADAKVEO,Crizanlizumab-tmca,Sickle Cell Disease,5 mg/kg,Every 4 weeks,Over 30 minutes,Injection 100mg/10mL,10mL vial,NS or D5W,N/A,"Headache, nausea, back pain, arthralgia",100-500mL NS or D5W,Yes,None required,0.2 micron in-line filter,Store refrigerated 2-8°C,4 hours at room temperature,None,Dilute in 100mL for ≤100kg or 500mL for >100kg,Monitor for infusion reactions,Not established
OXBRYTA,Voxelotor,Sickle Cell Disease,1500 mg,Once daily,Oral,Tablets 500mg,N/A,N/A,N/A,"Headache, diarrhea, abdominal pain, nausea",N/A,N/A,N/A,N/A,Store at room temperature,N/A,None,Take with or without food,May cause laboratory interference,Not established
ENDARI,L-glutamine,Sickle Cell Disease,5-15 g,Twice daily,Oral,Powder packets 5g,N/A,N/A,N/A,"Constipation, nausea, headache, abdominal pain",N/A,N/A,N/A,N/A,Store at room temperature,N/A,None,Mix with cold or room temperature beverage or food,Take with meals,Category C